Bayer Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bill Anderson

Chief executive officer

€11.8m

Total compensation

CEO salary percentage	14.3%
CEO tenure	1.6yrs
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Anderson's remuneration changed compared to Bayer's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

Compensation vs Market: Bill's total compensation ($USD12.50M) is above average for companies of similar size in the Swiss market ($USD4.76M).

Compensation vs Earnings: Insufficient data to compare Bill's compensation with company performance.

CEO

Bill Anderson (58 yo)

1.6yrs

Tenure

€11,804,104

Compensation

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Anderson	Chairman of the Management Board & CEO	1.6yrs	€11.80m	no data
Wolfgang Nickl	CFO & Member of Management Board	6.6yrs	€3.42m	no data
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	6yrs	€3.43m	no data
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.8yrs	€3.65m	no data
Heike Prinz	Chief Talent Officer	1.2yrs	€2.53m	no data
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	no data	no data
Sebastian Guth	Chief Operating Officer	less than a year	no data	no data
Amanda McClerren	Chief Information Officer	less than a year	no data	no data
Jost Reinhard	Head of Investor Relations	1.1yrs	no data	no data
Thomas Laubert	Head of Law	1.3yrs	no data	no data
Michael Preuss	Head of Communications	8.5yrs	no data	no data
Bernd-Peter Bier	Head of Group Finance	no data	no data	no data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Management: BAYN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul M. Achleitner	Member of Supervisory Board	22.6yrs	€225.00k	no data
Ertharin Cousin	Independent Member of the Supervisory Board	5.1yrs	€270.00k	no data
Heinz Webers	Employee Representative Member of Supervisory Board	2.6yrs	€205.00k	no data
Simone Bagel-Trah	Independent Member of Supervisory Board	10.6yrs	€227.00k	no data
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	no data	no data
Lori Schechter	Independent Supervisory Board Member	less than a year	no data	no data
Horst Baier	Independent Member of Supervisory Board	4.6yrs	€333.00k	no data
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.6yrs	€346.00k	no data
André van Broich	Member of Supervisory Board	12.6yrs	€271.00k	no data
Otmar Wiestler	Independent Member of Supervisory Board	10.1yrs	€237.00k	no data
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.5yrs	€509.00k	no data
Gunter Hilken	Chairman of Executive Board - Currenta	no data	no data	no data

7.0yrs

Average Tenure

66.5yo

Average Age

Experienced Board: BAYN's board of directors are considered experienced (7 years average tenure).

Bayer Management

Management criteria checks 1/4

Key information

Recent management updates

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

New major risk - Share price stability

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Now 54% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Now 38% undervalued after recent price drop

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 44% undervalued after recent price drop

Now 45% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Now 64% undervalued after recent price drop

Bayer Announces Pharmacodynamic Data on Kerendia

Investor sentiment deteriorates as stock falls 66%

Investor sentiment deteriorates as stock falls 66%

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 66%

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Investor sentiment deteriorates as stock falls 66%

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Investor sentiment deteriorates as stock falls 66%

Now 55% undervalued after recent price drop

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 66%

Now 44% undervalued after recent price drop

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age